European screening standards recommend more frequent screening for oncogene-addicted NSCLC patients, and clinical trials are investigating screening for BM in hormone receptor+, HER2+, and TN breast cancers. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.